000			04057nam a22004335i 4500
003			ESmaUEC
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
040			_aES-MaUEC _bspa _cES-MaUEC
336			_aTexto _btxt _2rdacontent
710	2		_aSpringerLink (Online service) _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
999			_c100828 _d100828 _x1
001			100828
005			20230102113013.0
008			180327s2018 gw | s |||| 0|eng d
020			_a9783662558805
024	7		_a10.1007/978-3-662-55880-5 _2doi
050		4	_aRM324.8 _b2018 EB
245	1	0	_aBehavioral Neurobiology of Psychedelic Drugs _cedited by Adam L. Halberstadt, Franz X. Vollenweider, David E. Nichols.
264		1	_aBerlin _bSpringer International Publishing _c2018
300			_a1 recurso en línea (X, 430 páginas 196 ilustraciones,158 ilustraciones a color)
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCurrent Topics in Behavioral Neurosciences, _x1866-3370 _v36
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aPreface -- Chemistry and structure-activity relationships of psychedelics -- Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways -- Effects of hallucinogens on neuronal activity -- Interactions of Hallucinogens with the Glutamatergic System:  Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons -- The effects of hallucinogens on gene expression -- Effect of Hallucinogens on Unconditioned Behavior -- Hallucinogens in Drug Discrimination -- Phenomenology, structure and dynamic of psychedelic states -- Serotonergic hallucinogen-induced visual perceptual alterations -- New world tryptamine hallucinogens and the neuroscience of ayahuasca -- Experimental psychosis research and schizophrenia - similarities and dissimilarities in psychopathology -- A review of Hallucinogen Persisting Perception Disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD -- Therapeutic applications of classic hallucinogens -- Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
520	3		_aThis volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action.  Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.
988			_aEBSPRINGER_2018
650		7	_aAlucinógenos _2embne _9141357
650		7	_aDrogas _2embne _9139235
700	1		_aHalberstadt, Adam L. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n2018186823 _1http://viaf.org/viaf/14153530967348702856
700	1		_aVollenweider, Franz X. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/n2018186824 _1http://viaf.org/viaf/7153530952348702868
700	1		_aNichols, David E. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt _0http://id.loc.gov/authorities/names/no00036785 _1http://viaf.org/viaf/51371836
776	0	8	_iEdición impresa: _z9783662558782
776	0	8	_iEdición impresa: _z9783662558799
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-662-55880-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b04/2019 _dz _ea _zSI